-
A COST OUTCOMES ANALYSIS OF APIXABAN VERSUS RIVAROXABAN FOR THE TREATMENT OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
APTITUDE TOWARDS PATIENT-CENTERED CARE AMONG PHYSICIANS MANAGING RARE DISEASES IN THE UNITED STATES: A CROSS-SECTIONAL SURVEY
Mar 18, 2026, 21:38 PM -
LEVERAGING GENERATIVE AI AND MACHINE LEARNING FOR ROBUST REAL-WORLD COHORT DEFINITION AND PATIENT JOURNEY INSIGHTS IN HIV RESEARCH
Mar 18, 2026, 21:38 PM -
ORPHAN CELL AND GENE THERAPY APPROVALS IN THE US AND EUROPE: A COMPARATIVE ANALYSIS
Mar 18, 2026, 21:38 PM -
EARLY REAL-WORLD ADHERENCE TO MRI SAFETY SURVEILLANCE AFTER LECANEMAB INITIATION AMONG MEDICARE BENEFICIARIES
Mar 18, 2026, 21:38 PM -
US PAYER CURRENT AND FUTURE ADOPTION OF ARTIFICIAL INTELLIGENCE
Mar 18, 2026, 21:38 PM -
REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH EGFR-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER
Mar 18, 2026, 21:38 PM -
A QUALITATIVE ANALYSIS OF RECENT NEW HEALTH TECHNOLOGY ASSESSMENT CASES AND EVALUATION TRENDS FOR THE ADOPTION OF NOVEL TECHNOLOGIES
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS VERSUS SGLT2 INHIBITORS FOR CARDIOVASCULAR PROTECTION AMONG U.S. ADULTS WITH DIABETES: A MEPS-BASED ECONOMIC EVALUATION 2022
Mar 18, 2026, 21:38 PM -
TYPE 2 COMORBIDITIES IN PATIENTS INITIATING DUPILUMAB FOR ASTHMA: REAL-WORLD EVIDENCE FROM A NATIONAL US DATABASE
Mar 18, 2026, 21:38 PM -
COMPARATIVE CARDIOVASCULAR RISK IN U.S. POSTMENOPAUSAL WOMEN STARTING ROMOSOZUMAB VS DENOSUMAB: A HIGH-DIMENSIONAL INVERSE PROBABILITY OF SELECTION WEIGHTING ANALYSIS FOR MISSING CARDIOVASCULAR RISK FACTORS
Mar 18, 2026, 21:38 PM -
IMPLEMENTATION OF EMBEDDED QUALITATIVE INTERVIEWS IN CLINICAL TRIALS: INSIGHTS FROM THE LITERATURE
Mar 18, 2026, 21:38 PM -
STANDARDIZING AI MODEL INTERACTION WITH HEALTHCARE SYSTEMS USING THE MODEL CONTEXT PROTOCOL (MCP)
Mar 18, 2026, 21:38 PM -
ASSESSING PRIORITIES IN ETHNICALLY DIVERSE CAREGIVERS FOR PEOPLE WITH AGITATION IN ALZHEIMER'S DEMENTIA
Mar 18, 2026, 21:38 PM -
REAL-WORLD FRONT-LINE USE OF ENFORTUMAB VEDOTIN - PEMBROLIZUMAB (EV+P) AFTER ADJUVANT NIVOLUMAB IN ADVANCED UROTHELIAL CANCER(AUC)
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION WITH RECOMBINANT ADAMTS13 IN PATIENTS WITH CONGENITAL TTP: RESULTS FROM A PHASE 3 RANDOMIZED CLINICAL TRIAL
Mar 18, 2026, 21:38 PM -
TREATMENT PATTERNS AND GAPS IN RESECTABLE MUCOSAL MELANOMA CARE FOR MEDICARE BENEFICIARIES IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
ASSESSING HEALTH SERVICE VARIATIONS BY DEGREE OF URBANIZATION IN NEPAL
Mar 18, 2026, 21:38 PM -
DISTINCT CARE PATHWAYS AND ECONOMIC IMPACT IN TREATED GEP-NET: A U.S. CLAIMS ANALYSIS OF METASTATIC VS NON-METASTATIC DISEASE
Mar 18, 2026, 21:38 PM -
FRAMEWORK FOR RWD TRANSFORMATIONS FROM NATIVE DATA MODELS TO CDISC DATA STANDARDS
Mar 18, 2026, 21:38 PM
